Hims stock rose on Tuesday after the compounding facility announced plans to offer Eli Lilly’s (LLY) branded weight-loss medicine, Zepbound, through its telehealth platform.
The announcement is a significant boost for Hims & Hers Health. The Food and medicine Administration prohibited copycat copies of tirzepatide, the chemical backbone of Zepbound, last month, claiming that the medicine was no longer in low supply. The decision forced compounders to scramble to cover an expected gap in their topline. Some businesses have said that they will sell personalised doses of the compounded medicine.
However, Hims & Hers intends to sell Zepbound-branded products instead. Patients will also be able to access generic liraglutide via Hims’ platform. Liraglutide, often known as Victoza, is a type 2 diabetes medication developed by Novo Nordisk. It works similarly to Novo’s Wegovy, mimicking the GLP-1 hormone to reduce appetite and enhance blood sugar levels.
Hims shares rose 5.3% to close at 31.10. Shares are attempting to reclaim their 50-day line.
Hims Stock: Surviving the Food and Drug Agency’s Decision
Hims Stock & Hers is not the only compounder that sells branded Zepbound. Teladoc Health (TDOC), LifeMD (LFMD), and Ro.com all offer branded Zepbound on their own platforms.
Eli Lilly asserts the corporation has no association with Hims & Hers.
“Zepbound can be prescribed by any licensed healthcare professional,” a firm spokesman told Investor’s firm Daily via email. “People who have commercial insurance with Zepbound coverage may be able to pay as little as $25.” Zepbound is provided on LillyDirect for $349 per month for self-paying customers.
Hims Stock argues that supplying branded Zepbound offers the most option for each patient.
“For some, that can mean access to a broad range of weight loss medications, including compounded, generic, and branded options,” Hims & Hers highlighted in a press statement. “For others, it might mean working with their care team to better understand their diet, exercise, and behavioral patterns in the app.”
Hims stock has recently been on a roller coaster. On February 19, shares reached a record high, bolstered by plans to provide at-home lab testing through its platform. Shares have plummeted in recent weeks, dropping roughly 54% from their all-time high.
People often wonder
who owns HIMS Stock.
CEO Andrew Dudum, Hilary Coles, Jack Abraham, and Joe Spector launched Hims & Hers at San Francisco’s Atomic Venture Studio. For more information about Hims & Hers, go to forhims.com and forhers.com. Source: His and Hers Health, Inc.
Is HIMS Stock traded?
For example, on the the New York Stock Exchange Hims & Hers Health, Inc. equities are traded under the ticker HIMS. Is Hims & Hers Health, Inc.’s stock price increasing? HIMS stock fell by −10.61% compared to the previous week, with a month change of −27.58%. Over the last year, Hims & Hers Health, Inc. has had an 87.14% growth.
What is the valuation of HIMS Stock?
Valuation Measures
| Current | 12/31/2024 | |
|---|---|---|
| Market Cap | 6.47B | 5.28B |
| Enterprise Value | 6.18B | 5.04B |
| Trailing P/E | 54.98 | 54.95 |
| Forward P/E | 49.02 | 49.75 |
How does the HIMS Stock make its money?
Hims & Hers works on a direct-to-consumer approach. The company’s platform allows consumers to interact with qualified healthcare specialists and obtain treatments and goods. Customers pay for a consultation with a doctor before being prescribed the medicine, as well as the cost of the drug.
How much does Hims cost?
How much does Hims cost? Hims costs $49 per month and is invoiced every three months at $147. All Hims Stock mental health pharmaceutical plans include 24/7 messaging assistance with your physician, as well as medicine and delivery costs. Hims doesn’t take insurance.
KEY STATS
- Open29.70
- Day High33.70
- Day Low28.76
- Prev Close29.55
- 52 Week High72.98
- 52 Week High Date02/19/25
- 52 Week Low11.20
- 52 Week Low Date05/03/24
- Market Cap6.898B
- Shares Out222.17M
- 10 Day Average Volume21.60M
- Dividend–
- Dividend Yield–
- Beta1.65
- YTD % Change28.41
RATIOS/PROFITABILITY
- EPS (TTM)0.54
- P/E (TTM)57.89
- Fwd P/E (NTM)48.14
- EBITDA (TTM)85.148M
- ROE (TTM)30.71%
- Revenue (TTM)1.477B
- Gross Margin (TTM)79.45%
- Net Margin (TTM)8.54%
- Debt To Equity (MRQ)
EVENTS
- Earnings Date05/05/2025(est)
- Ex Div Date–
- Div Amount–
- Split Date–
- Split Factor
Startup Hims & Hers shares increase after adding additional weight-loss drugs to its site.
Key Points : Hims Stock
- Hims & Hers Health is expanding its platform to include Eli Lilly’s weight loss prescription Zepbound, diabetes treatment Mounjaro, and generic injectable liraglutide.
- The company’s GLP-1 solutions have changed as it has dealt with a variable supply and regulatory landscape.
- The stock finished 5% higher on Tuesday.
On Tuesday, Hims & Hers Health saw a 5% increase in shares after announcing the availability of Eli Lilly’s weight loss prescription Zepbound, diabetes treatment Mounjaro, and generic injectable liraglutide on its site.
Zepbound, Mounjaro, and liraglutide belong to a family of weight reduction drugs known as GLP-1s, which have grown in popularity recently. Hims & Hers introduced a weight reduction program in late 2023, but its GLP-1 products have varied as the firm dealt with a fluctuating supply and regulatory environment.
Lilly’s weekly injections Zepbound and Mounjaro will cost patients $1,899 every month, according to the Hims & Hers website. The generic liraglutide costs $299 a month, but it needs daily injections and may be less effective than other GLP-1 drugs.
“As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience,” Dr. Craig Primack, senior vice president of weight loss at Hims & Hers, said in a blog post.
According to a Lilly spokeswoman, the firm has “no affiliation” with Hims & Hers and that Zepbound is more affordable for customers who are insured for the medicine or who purchase straight from the brand.
In May, Hims & Hers began prescribing compounded semaglutide, which is the active component in Novo Nordisk’s GLP-1 weight reduction drugs Ozempic and Wegovy. The product was very successful, generating over $225 million in income for the corporation in 2024.
However, compounded pharmaceuticals can historically only be bulk manufactured when branded medications and therapies are in low supply. In February, the US Food and Drug Administration declared that the shortage of semaglutide injectable products had been addressed.
As a result, Hims & Hers had to generally discontinue the compounded pharmaceuticals, while certain customers may still be able to get individualized dosages if they are clinically suitable.
During the company’s quarterly call with investors in February, Hims & Hers said that its weight loss products will predominantly include oral medicines and liraglutide. The business estimates that its weight reduction services will produce at least $725 million in yearly revenue, excluding contributions from compounded semaglutide.
However, the corporation is still pushing for compounded pharmaceuticals. A pop-up on the Hims & Hers website, seen by CNBC, asks readers to “use your voice” and push Congress and the FDA to protect access to compounded medications.
With Tuesday’s rise, Hims and Hers shares are up approximately 27% in 2025, after a 172% increase last year.
Hims Review 2025: Pros and Cons, Cost, and My Experience.
Hims Stock , part of Hims & Hers Health, Inc., handles a variety of men’s health issues. The platform promotes therapies for problems that some men may find humiliating or difficult to discuss, such as sexual health (e.g., premature ejaculation and erectile dysfunction), hair loss, weight loss, and mental health.
Medication prescriptions are issued via Hims after you complete a detailed health questionnaire that is assessed by a board-certified health practitioner in your state. The first online examination takes around 10 minutes. The provider evaluation is usually finished in less than 12 hours.
Hims Stock costs $49 a month, which is invoiced quarterly for $147. While it is accessible and handy, it does not take insurance; nonetheless, savings are offered for the first prescription. Care is based on written evaluations and conversation, with no live appointments. This may work for some people, but it is not recommended for individuals who are new to medicine, need extensive care, or wish to utilize insurance.
Talkiatry is our top choice for a more complete psychiatric service, however it is only accessible to individuals with insurance in 43 US states, while serving people of all ages (5 and above). Brightside Health is our top option for cash-pay psychiatry since it provides complete treatment for adults on a monthly subscription basis. For other possibilities, see our list of the finest online psychiatric platforms.
Detailed Hims Review
We rated Hims Stock three out of five stars. They received great marks for affordability, and we enjoyed their ability to simply prescribe medicine online. However, we did not enjoy the fact that they do not take insurance or provide treatment. Our primary worry is the low-touch care approach, which reduces direct, in-person connection between patients and providers.
Continue reading for a thorough analysis of our experience, as well as our score breakdown:
Getting a Prescription
The next Monday, I received a message informing me that my prescription, which I had not yet formally committed to, was in the mail and on its way to me. This caught me by surprise. Didn’t I need to see a psychiatrist first? I assumed that starting on a maintenance dosage would be simpler than being given new medication. But I was still worried because Hims did not seek corroboration from my former doctor. The only documents I needed to submit were a copy of my driver’s license and a selfie for identification verification.
We decided to have another member of our team try Hims and see what happens when they complete out the intake. This employee has never been on mental health medicine before. Hims Stock continued to give them medicine without any meetings with a psychiatrist or follow-up consultations. The diagnosis and subsequent medication seem to be solely based on this one intake questionnaire.
Oddly, the system did not request any kind of identification or driver’s license this time. Our staff member requested a one-on-one appointment with a physician to discuss this further via their provider portal, but customer service informed them that since this is not a legal requirement in the patient’s state, they are unable to give it.
Cost and Insurance
Hims stock costs $49 per month but is invoiced at $147 every three months. All Hims price options for mental health medications include continuous messaging assistance with your physician, as well as drug and delivery costs.
Hims doesn’t take insurance. It only takes HSAs and FSAs as payment for weight loss procedures.
User Reviews
Hims Stock consistently receives favorable ratings across numerous review sites. Many people believe that the services and goods provided are actually beneficial and cheap. Customer service, invoicing, and criticisms of the entire care model are the most common complaints raised in unfavorable evaluations.
It’s worth mentioning that many good evaluations on third-party review websites are about hair loss treatment and sexual health, thus they may not accurately reflect Hims mental health therapy.
Pros & Cons
Pros
- Accept most major insurances
- Treats kids (5+), teens, & adults
Cons
- Doesn’t accept cash-pay
- Therapy only for existing patients
